Chronic thromboembolic pulmonary hypertension(CTEPH) is the WHO group 4 category of pulmonary *** is classically thought to occur in a subset of survivors of acute pulmonary embolism (PE),but only about 70%of CTEPH pa...
详细信息
Chronic thromboembolic pulmonary hypertension(CTEPH) is the WHO group 4 category of pulmonary *** is classically thought to occur in a subset of survivors of acute pulmonary embolism (PE),but only about 70%of CTEPH patients have a known history of *** potential etiologies include
In the recent decade many advances have been achieved in the field of treatments for pulmonary arterial hypertension(PAH).Prostacyclin and its derivates,blockers of endothelin receptors and inhibitors of the phosphodi...
详细信息
In the recent decade many advances have been achieved in the field of treatments for pulmonary arterial hypertension(PAH).Prostacyclin and its derivates,blockers of endothelin receptors and inhibitors of the phosphodiesterase-5 represent the currently approved classes of drugs in this *** all currently approved medications have shown to improve exercise capacity,quality of life and prognosis of
Pulmonary arterial hypertension(PAH)is characterised by progressive remodelling in the distal pulmonary arteries leading to increased pulmonary vascular resistance and thus right ventricular *** leads ultimately to ri...
详细信息
Pulmonary arterial hypertension(PAH)is characterised by progressive remodelling in the distal pulmonary arteries leading to increased pulmonary vascular resistance and thus right ventricular *** leads ultimately to right ventricular failure and *** traditional view of chronic thromboembolic pulmonary hypertension(CTEPH)is that is results following an episode of pulmonary embolism(PE)which
There are now over 20 published randomized clinical trials assessing treatments for pulmonary arterial *** studies involving some 1500 patients provide a rich evidence base for the current management of these *** stud...
详细信息
There are now over 20 published randomized clinical trials assessing treatments for pulmonary arterial *** studies involving some 1500 patients provide a rich evidence base for the current management of these *** studies,together with patient registries,also provide some
Pulmonary arterial hypertension (PAH) is characterised by progressive remodelling in the distal pulmonary arteries leading to increased pulmonary vascular resistance and thus right ventricular afterload. This leads ul...
详细信息
Pulmonary arterial hypertension (PAH) is characterised by progressive remodelling in the distal pulmonary arteries leading to increased pulmonary vascular resistance and thus right ventricular afterload. This leads ultimately to right ventricular failure and death. The traditional view of chronic thromboembolic pulmonary hypertension (CTEPH) is that is results following an episode of pulmonary embolism (PE) which fails to resolve. However, we know that CTEPH is also a progressive condition even when further PEs arebeing prevented with anticoagulation. This progression most likely comes from a progressive pulmonary vascular remodelling process, which in many ways is indistinguishable from the changes seen microscopically in PAH.
Individual clinical trials and meta-analyses comparing low molecular weight heparins(LMWHs) to unfractionated heparin(UFH) for treatment of venous thromboembolism(VTE) show similar efficacy and safety,with perhaps som...
详细信息
Individual clinical trials and meta-analyses comparing low molecular weight heparins(LMWHs) to unfractionated heparin(UFH) for treatment of venous thromboembolism(VTE) show similar efficacy and safety,with perhaps somewhat less bleeding favoring the ***,these meta-analyses data are approximations of the truth,because the prevalence of clinically important bleeding is too low in most studies for statistical significance,the LMWHs,their dosages,and their regimens differ in the studies,and of course,the patients are *** sought to compare characteristics of patients with acute PE randomized to either UFH or LMWH(nadroparin 86 aXa U/kg sq q 12 h) to determine if patient's weight, age,degree of baseline pulmonary arterial obstruction(PAO),and degree of resolution of PVO at day 14 was associated with the primary efficacy outcome of recurrence or death,and the safety outcome of any bleeding by day 14.
Pulmonary arterial hypertension(PAH)is a lethal and intractable disease of progressive vascular *** distinctive obliterative vascular remodelling in idiopathic PAH(IPAH)patient lungs involves all cellular elements of ...
详细信息
Pulmonary arterial hypertension(PAH)is a lethal and intractable disease of progressive vascular *** distinctive obliterative vascular remodelling in idiopathic PAH(IPAH)patient lungs involves all cellular elements of the vessel wall and leads to increases in pulmonary vascular resistance (PVR)and so pulmonary artery pressure(PAP).Novel drugs targeted directly at halting or reversing the
Background—Prior studies have shown that PI3K]Akt pathway plays a necessary role in plaelete activation and arterial thrombus *** studies yet have explored the role of PI3K or Akt in venous *** our study,the role of ...
详细信息
Background—Prior studies have shown that PI3K]Akt pathway plays a necessary role in plaelete activation and arterial thrombus *** studies yet have explored the role of PI3K or Akt in venous *** our study,the role of Akt2,one isoform of Akt,was investigated using mice model of venous thrombosis.
Pulmonary thromboembolism(PTE) is a common clinical problem that is associated with substantial morbidity and *** protein C(PC) play an essential role in regulation of thrombin activity,we investigated the role of PC ...
详细信息
Pulmonary thromboembolism(PTE) is a common clinical problem that is associated with substantial morbidity and *** protein C(PC) play an essential role in regulation of thrombin activity,we investigated the role of PC polymorphism in patients with pulmonary *** hundred and ten cases of PTE and one hundred and ninety healthy control
暂无评论